Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mastocytosis: One Word for Different Diseases

Mastocytosis: One Word for Different Diseases Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different degrees of aggressiveness. Mastocytosis is often a multiorgan disease, and its correct management requires a multidisciplinary team of experienced consultants to provide overall patient care. Bone marrow evaluation by molecular analyses, skeleton X-ray and abdominal scan together with allergologic and dermatologic evaluation constitute the essential diagnostic work-up for adult patients with mastocytosis. As clinical situations vary, treatment options range from the use of drugs to treat the symptoms, such as anti-H1 receptors and steroids, to UV irradiation, which is overwhelmingly used in patients with cutaneous mastocytosis (CM) or indolent systemic mastocytosis, to cytoreductive treatment to control life-threatening symptoms or organ damage in the more aggressive forms of the disease. Prognosis also widely differs among patients diagnosed with mastocytosis, with the spectrum ranging from an almost normal life expectancy for those with CM and to less than 1-year median overall survival for those with mast cell leukemia. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Mastocytosis: One Word for Different Diseases

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/mastocytosis-one-word-for-different-diseases-JEtaDv67nH
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0086-2
Publisher site
See Article on Publisher Site

Abstract

Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different degrees of aggressiveness. Mastocytosis is often a multiorgan disease, and its correct management requires a multidisciplinary team of experienced consultants to provide overall patient care. Bone marrow evaluation by molecular analyses, skeleton X-ray and abdominal scan together with allergologic and dermatologic evaluation constitute the essential diagnostic work-up for adult patients with mastocytosis. As clinical situations vary, treatment options range from the use of drugs to treat the symptoms, such as anti-H1 receptors and steroids, to UV irradiation, which is overwhelmingly used in patients with cutaneous mastocytosis (CM) or indolent systemic mastocytosis, to cytoreductive treatment to control life-threatening symptoms or organ damage in the more aggressive forms of the disease. Prognosis also widely differs among patients diagnosed with mastocytosis, with the spectrum ranging from an almost normal life expectancy for those with CM and to less than 1-year median overall survival for those with mast cell leukemia.

Journal

Oncology and Therapy – Springer Journals

Published: Oct 29, 2018

References

  • Epidemiology of systemic mastocytosis in Denmark
    Cohen, SS; Skovbo, S; Vestergaard, H; Kristensen, T; Møller, M; Bindslev-Jensen, C
  • WHO classification of tumors of hematopoietic and lymphoid tissues
    Horny, HP; Metcalfe, DD; Bennett, JM
  • Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
    Hartmann, K; Escribano, L; Grattan, C; Brockow, K; Carter, MC; Alvarez-Twose, I
  • Pattern analysis of human cutaneous mast cell populations by total body surface mapping
    Weber, A; Knop, J; Maurer, M
  • Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology
    Brockow, K; Akin, C; Huber, M; Metcalfe, DD
  • Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)
    González de Olano, D; Hoz Caballer, B; Núñez López, R; Sánchez Muñoz, L; Cuevas Agustín, M; Diéguez, MC
  • Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
    Brockow, K; Jofer, C; Behrendt, H; Ring, J
  • High prevalence of anaphylaxis in patients with systemic mastocytosis—a single-centre experience
    Gülen, T; Hägglund, H; Dahlén, B; Nilsson, G
  • Disease spectrum in patients with elevated serum tryptase levels
    Aberer, E; Savic, S; Bretterklieber, A; Reiter, H; Berghold, A; Aberer, W
  • How much specific is the association between hymenoptera venom allergy and mastocytosis?
    Bonadonna, P; Zanotti, R; Pagani, M; Caruso, B; Perbellini, O; Colarossi, S
  • Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels
    Bonadonna, P; Perbellini, O; Passalacqua, G; Caruso, B; Colarossi, S; Fior, D
  • KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis
    Broesby-Olsen, S; Kristensen, T; Vestergaard, H; Brixen, K; Møller, MB; Bindslev-Jensen, C
  • Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM)
    Valent, P; Aberer, E; Beham-Schmid, C; Fellinger, C; Fuchs, W; Gleixner, KV
  • Gastrointestinal manifestations of hypereosinophilic syndromes and mast cell disorders: a comprehensive review
    Nanagas, VC; Kovalszki, A
  • Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study
    Broesby-Olsen, S; Farkas, DK; Vestergaard, H; Hermann, AP; Møller, MB; Mortz, CG
  • Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal
    Valent, P; Sotlar, K; Sperr, WR; Escribano, L; Yavuz, S; Reiter, A
  • Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture
    Valent, P; Spanblöchl, E; Sperr, WR; Sillaber, C; Zsebo, KM; Agis, H
  • Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management
    Pardanani, A
  • The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease
    Hoermann, G; Gleixner, KV; Dinu, GE; Kundi, M; Greiner, G; Wimazal, F
  • Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
    Jawhar, M; Schwaab, J; Schnittger, S; Sotlar, K; Horny, HP; Metzgeroth, G
  • Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis
    Jawhar, M; Schwaab, J; Schnittger, S; Meggendorfer, M; Pfirrmann, M; Sotlar, K
  • CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis
    Morgado, JM; Perbellini, O; Johnson, RC; Teodósio, C; Matito, A; Álvarez-Twose, I
  • Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study
    Lortholary, O; Chandesris, MO; Bulai Livideanu, C; Paul, C; Guillet, G; Jassem, E; Niedoszytko, M
  • Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations
    Broesby-Olsen, S; Vestergaard, H; Mortz, CG; Jensen, B; Havelund, T; Hermann, AP
  • Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis
    Rossini, M; Zanotti, R; Orsolini, G; Tripi, G; Viapiana, O; Idolazzi, L
  • Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    Lim, KH; Pardanani, A; Butterfield, JH; Li, CY; Tefferi, A
  • Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
    Barete, S; Lortholary, O; Damaj, G; Hirsch, I; Chandesris, MO; Elie, C
  • A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
    Akin, C; Fumo, G; Yavuz, AS
  • Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
    Verstovsek, S; Tefferi, A; Cortes, J; O’Brien, S; Garcia-Manero, G; Pardanani, A
  • Efficacy and safety of midostaurin in advanced systemic mastocytosis
    Gotlib, J; Kluin-Nelemans, HC; George, TI; Akin, C; Sotlar, K; Hermine, O
  • Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers
    Jawhar, M; Schwaab, J; Naumann, N; Horny, HP; Sotlar, K; Haferlach, T
  • Advances in the classification and treatment of mastocytosis: current status and outlook toward the future
    Valent, P; Akin, C; Hartmann, K; Nilsson, G; Reiter, A; Hermine, O
  • Hematopoietic stem-cell transplantation for advanced systemic mastocytosis
    Ustun, C; Reiter, A; Scott, BL; Nakamura, R; Damaj, G; Kreil, S
  • Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
    Arock, M; Wedeh, G; Hoermann, G; Bibi, S; Akin, C; Peter, B
  • Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin
    Borate, U; Mehta, A; Reddy, V; Tsai, M; Josephson, N; Schnadig, I
  • The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
    Schneeweiss, M; Peter, B; Bibi, S; Eisenwort, G; Smiljkovic, D; Blatt, K
  • Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria
    Valent, P; Akin, C; Sperr, WR; Escribano, L; Arock, M; Horny, HP
  • A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions
    Pardanani, A; Tefferi, A
  • International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
    Gotlib, J; Pardanani, A; Akin, C; Reiter, A; George, T; Hermine, O
  • Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish network on mastocytosis (REMA) based on 726 anesthetic procedures
    Matito, A; Morgado, JM; Sánchez-López, P; Álvarez-Twose, I; Sánchez-Muñoz, L; Orfao, A
  • Management around invasive procedures in mastocytosis: An update
    Hermans, MAW; Arends, NJT; Gerth van Wijk, R; Hagen, PM; Kluin-Nelemans, HC; Oude Elberink, HNG
  • Clinical impact of pregnancy in mastocytosis: a study of the Spanish network on mastocytosis (REMA) in 45 cases
    Matito, A; Álvarez-Twose, I; Morgado, JM; Sánchez-Muñoz, L; Orfao, A; Escribano, L